Methods We obtained the data from PubMed, Scopus, Embase, and Web of Science for all eligible studies, including clinical trials (RCT) and cohorts comparing GLP-1 RAs to placebo or other hypoglycemic agents in patients with HFpEF published until December 31st, 2024
Last reviewed: June 6, 2026 Last updated: June 6, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
The new study reflects this growing practice
Why Semaglutide Causes Side Effects: The Mechanism Behind Discomfort Semaglutide activates GLP-1 receptors throughout your gastrointestinal tract and brain, triggering three primary effects: delayed gastric emptying, reduced appetite signaling, and slowed intestinal motility